Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections

Key Points

• The aim is to compare the effectiveness and resistance outcomes of ceftazidime-avibactam and meropenem-vaborbactam in KPC-producing Enterobacterales infections.
• Analyzed a cohort of 73 patients with KPC-producing Enterobacterales infections
• Used propensity-score weighting to balance group characteristics
• Assessed both mortality rates and emergence of resistance.
• Thirty-day mortality rates were similar for both treatments
• Resistance emerged more frequently in the ceftazidime-avibactam group (12% vs 0%)
• Identified resistance mechanisms included porin mutations and structural changes in AmpC.

Abstract